Lyndann Sokolowski
Family · North Platte, NENPI 1831380740
Payments from drug & device makers
Across 115 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$714
- Novo Nordisk$369
- AstraZeneca$279
- Lilly USA, LLC$153
- Johnson & Johnson$90
- Pfizer$31
- plus $203 from 11 others
What the payments were for
- Food & beverage$1,839100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $714 |
| Novo Nordisk | 18 | $369 |
| AstraZeneca | 4 | $279 |
| Lilly USA, LLC | 10 | $153 |
| Johnson & Johnson | 2 | $90 |
| Pfizer | 2 | $31 |
| GSK | 2 | $28 |
| Merck | 2 | $27 |
| Daiichi Sankyo Inc. | 2 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,839 in reported general payments places this provider in the 80th percentile of 809 family providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex Pen (4 Pack)Interferon Beta-1a | 11 | $96,056 |
| MyrbetriqMirabegron | 18 | $5,438 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $5,160 |
| EliquisApixaban | 11 | $3,170 |
| Baclofen | 11 | $559 |
| Dilt-XrDiltiazem Hcl | 12 | $420 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $413 |
| Bumetanide | 12 | $398 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $366 |
| Atorvastatin Calcium | 18 | $335 |
| Amlodipine Besylate | 17 | $249 |
| Ramipril | 12 | $243 |
| Potassium Chloride | 15 | $196 |
| Carvedilol | 14 | $179 |
| Pantoprazole Sodium | 16 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $17 | $5,43818 claims |
| MerckJanumet Xr | $27 | $5,16018 claims |
| PfizerEliquis | $31 | $3,17011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 809 family providers in Nebraska.
Other family in North Platte
- Kelley HasenauerNorth Platte$4K
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.